QUEBEC, June 13 /CNW Telbec/ - Victhom Human Bionics Inc. "Victhom" (TSX:
VHB) at its annual meeting of shareholders held on Monday June 11, 2007,
highlighted its progress in product development for its two business units.
Mr. Benoit Huet, President and CEO, updated the shareholders on the
progress made in product development in both business units. He mentioned that
the Biotronix business unit is now focusing its efforts on a new version of
the Power Knee in collaboration with its partner Ossur. As regards the
Neurobionix business unit, Mr. Huet highlighted the importance of the clinical
trial on the Neurostep(TM), a fully-implantable closed-loop peripheral
nerve-sensing and nerve-stimulating medical device. He also mentioned that the
Company expects to receive some preliminary results on the efficacy and safety
of the Neurostep(TM) by Q1 2008. The Neurostep(TM) is designed to treat,
through neuromodulation, gait disorders (e.g., foot drop) secondary to a
lesion of the central nervous system caused by conditions such as stroke or
Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom's Neurobionix business unit focuses on the development and
commercialization of technologies and products involving implantable devices
that feature neurosensing and neurostimulation components, integrated with
artificial intelligence. Victhom's Biotronix business unit develops
biomechatronic products to support or replace peripheral limbs in what is
known as the orthotics and prosthetics market.
Victhom's technologies and products are supported by a broad suite of
intellectual property, including a portfolio of 37 granted and 82 pending
patents filed in various countries and 13 registered trademarks, worldwide.
Victhom has established a comprehensive process to ensure the protection of
its intellectual property, pursuing filings for relevant discoveries and
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause Victhom's actual results, performance or achievements
to be materially different from those expressed or implied by any of the
Victhom's statements. Actual events or results may differ materially. We
disclaim any intention, and assume no obligation, to update these
For further information:
For further information: Mr. Benoit Huet, President & CEO, Victhom Human
Bionics Inc., (418) 872-5665, ext. 103, Fax: (418) 872-6926,
firstname.lastname@example.org, www.victhom.com; Source: Victhom Human Bionics Inc.